ArticleJournal of extracellular vesicles2026
Metabolic Tagging of Tumour Extracellular Vesicles for Targeted Modulation of Dendritic Cells.
Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Extracellular vesicles (EVs) have emerged as a promising alternative to cell-based therapies due to their benign safety profiles and favourable pharmacokinetic properties. Tumour EVs, in particular, have shown promise to function as a therapeutic cancer vaccine for various cancer types. However, the efficient and targeted delivery of EVs to dendritic cells, the prominent type of antigen-presenting cells in the body, remains a challenge. Here we report the metabolic tagging of tumour EVs with azido groups for subsequent conjugation of anti-DEC205 via efficient click chemistry. We showed that azido-sugars can metabolically label cancer cells with azido groups and that azido-labelled cells can secrete azido-tagged EVs. Anti-DEC205, upon facile modification with dibenzocyclooctyne, was successfully conjugated onto azido-tagged EVs. Anti-DEC205-conjugated EVs were preferentially internalized by dendritic cells over other types of immune cells, and improved the processing and presentation of EV-encased antigens by dendritic cells. We further demonstrated the ability of anti-DEC205-conjugated EVs to induce enhanced cytotoxic T lymphocyte responses and antitumor efficacy in comparison with control EVs. Our study provides a facile and universal approach to chemically tagging EVs and conjugating targeting moieties to EVs, for targeted modulation of cells of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.